已收盘 12-19 16:00:00 美东时间
+4.390
+20.76%
华尔街金融巨头摩根大通近日发布研报称,对于2025年美股市场的生物科技公司(即Biotech)股价走势持乐观看涨立场,预计Biotech有望跑赢美股大盘,其中美股Biotech领军者之一的福泰制药(VRTX.US)在摩根大通的2025年最佳Biotech选股名单中位列榜首。在美联储开启降息的大背景下,生物科技类股票可谓是最佳受益于降息周期的股票板块,在降息周期之下资金有望从近年来股价持续暴涨且估值处于历史高位的大型科技巨头们转向一些受益于降息周期且估值自2022年以来长期低迷的生物科技股。 据了解,在摩根大通最新发布的研报中,该机构2025年最看好的生物科技公司除了位列股票名单首选位置...
2024-11-26 15:22
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaini...
2024-09-20 02:57
U.S. stocks traded higher midway through trading, with the Dow Jones index jump...
2024-09-20 00:39
U.S. stocks were higher, with the Dow Jones index surging around 400 points on ...
2024-09-19 21:57
GLMD: 60% | Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years EWTX: 42% | Edgewise Therapeutics Announced Top-line Data
2024-09-19 20:06
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.
2024-09-18 02:57